The expression levels of certain nuclear receptors can serve as biomarkers for cancer prognosis. For instance, high expression of ER in breast cancer is generally associated with a better prognosis and a positive response to hormone therapy. Conversely, overexpression of some orphan nuclear receptors such as LRH-1 can correlate with poor prognosis in cancers like colorectal and pancreatic cancer. Thus, nuclear receptors can provide valuable information regarding the potential progression of the disease and guide treatment strategies.
